Preprint · OA
via OpenAlex
Proteostasis as a fundamental principle of Tau immunotherapy
Esteban Cruz, Rebecca M. Nisbet, Pranesh Padmanabhan, Ashley J. Waardenberg, Mark Evan Graham, Godfrey Nkajja, Swara Tapaswi, Philip J. Robinson, Jürgen Götz
bioRxiv (Cold Spring Harbor Laboratory) · 2024 · ▲ 2 citations
Abstract
Abstract The microtubule-associated protein Tau is a driver of neuronal dysfunction in Alzheimer’s disease and numerous other tauopathies. In this process, Tau initially undergoes subtle changes to its abundance, subcellular localisation and a vast array of post-translational modifications including phosphorylation, that progressively result in the protein’s aggregation and dysregulation of multiple Tau-dependent cellular processes. Given the various loss- and gain-of-functions of Tau in disease and the brain-wide changes in the proteome that characterise tauopathies, we asked whether targeting Tau would restore the alterations in proteostasis(definition) observed in disease. To this end, we generated a novel pan-Tau antibody, RNJ1, that preferentially binds human Tau and neutralises proteopathic seeding activity in multiple cell lines and benchmarked it against a clinically tested pan-Tau antibody, HJ8.5 (murine version of tilavonemab). We next evaluated both antibodies, alone and in combination, in the K3 mouse model of tauopathy, showing reduced Tau pathology and improvements in neuronal function following 14 weekly treatments, without obtaining synergistic effects for the combination treatment. To gain insight into molecular mechanisms contributing to improvements in neuronal function, we employed quantitative proteomics and phosphoproteomics to first establish alterations in K3 mice relative to WT controls at the proteome level. This revealed 342 proteins with differential abundance in K3 mice, which are predominantly involved in metabolic and microtubule-associated processes, strengthening previously reported findings of defects in several functional domains in multiple tauopathy models. We next asked whether antibody-mediated Tau target engagement indirectly affects levels of deregulated proteins in the K3 model. Importantly, both immunotherapies, in particular RNJ1, induced abundance shifts in this protein subset towards a restoration to wild-type levels (proteostasis). A total of 257 of 342 (∼75.1%) proteins altered in K3 were closer in abundance to WT levels after RNJ1 treatment. The same analysis indicated a similar response in K3 mice treated with HJ8.5, with approximately 72.5% of these altered proteins also showing changes in the same direction as wild-type. Furthermore, analysis of the phosphoproteome showed an even stronger restoration effect with RNJ1, with ∼82.1% of altered phosphopeptides in K3 showing a shift to WT levels, and 75.4% with HJ8.5. Gene set over-representation analysis (ORA) further confirmed that proteins undergoing restoration are involved in biological pathways affected in K3 mice. Together, our study suggests that a Tau immunotherapy-induced restoration of proteostasis links target engagement and treatment efficacy.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1101/2024.02.12.580007
- Canonical
- link ↗
- Fetched
- 2026-10-05 MST
Cite this
APA
Cruz, E., Nisbet, R.M., Padmanabhan, P., Waardenberg, A.J., Graham, M.E., Nkajja, G., Tapaswi, S., Robinson, P.J., & Götz, J. (2024). Proteostasis as a fundamental principle of Tau immunotherapy. <em>bioRxiv (Cold Spring Harbor Laboratory)</em>. https://doi.org/10.1101/2024.02.12.580007
Vancouver
Cruz E, Nisbet RM, Padmanabhan P, Waardenberg AJ, Graham ME, Nkajja G, et al. Proteostasis as a fundamental principle of Tau immunotherapy. bioRxiv (Cold Spring Harbor Laboratory). 2024. doi:10.1101/2024.02.12.580007.
BibTeX
@unpublished{esteban2024Proteo,
title = {Proteostasis as a fundamental principle of Tau immunotherapy},
author = {Esteban Cruz and Rebecca M. Nisbet and Pranesh Padmanabhan and Ashley J. Waardenberg and Mark Evan Graham and Godfrey Nkajja and Swara Tapaswi and Philip J. Robinson and Jürgen Götz},
journal = {bioRxiv (Cold Spring Harbor Laboratory)},
year = {2024},
doi = {10.1101/2024.02.12.580007},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cellular and Molecular Life Sciences 2019
Open access · CC-BY
Mechanisms of secretion and spreading of pathological tau protein
Journal of Alzheimer s Disease 2013
Open access · OA
Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy
Journal of Biological Chemistry 2010
Open access · CC-BY
AMP-activated Protein Kinase Signaling Activation by Resveratrol Modulates Amyloid-β Peptide Metabolism
Neural Regeneration Research 2015
Open access · CC-BY
Okadaic acid: a tool to study regulatory mechanisms for neurodegeneration and regeneration in Alzheimer′s disease
DR-NTU (Nanyang Technological University) 2015
Preprint · OA
Development and application of novel proteomics methods in proteomics research
Acta Pharmacologica Sinica 2018
Open access · OA